Support is requested to permit the University of California, Los Angeles, Center for the Health Sciences (UCLA/CHS) and its affiliated hospitals and physicians to continue participation as a full member in the scientific efforts of the Southwest Oncology Group (SWOG). UCLA/CHS affiliated hospitals include Olive View Medical Center (OVMC), Wadsworth Veterans Administration Medical Center (WVA), and Harbor General Hospital (HGH), and will be referred to as the University. The University entered SWOG as a probationary member in May 1990 with full membership status established in October 1991. Using the SWOG group mechanism as a multidisciplinary focus for clinical cancer research, the University's objectives include: (1) continue to further strengthen clinical cancer investigations at the University and within the NCI designated Jonsson Comprehensive Cancer Center (JCCC); (2) bridge the expertise in translational research within the University to strengthen SWOG's scientific efforts; (3) become major patient contributors to the group's phase III and multimodality studies with special emphasis on recruiting minority patients to clinical trials; and (4) enhance accrual by expanding the current University CGOP relationships to include the recently established UCLA/JCCC Network sites. Specifically, the University's aim is to continue its clinical research leadership by developing appropriate proposals in its areas of expertise, utilizing the University's translational and clinical strengths as they apply to: (1) the use of biological agents, products of molecular genetics, combination cytokine therapy, gene therapy, and cellular adoptive immunotherapy, in the treatment of solid tumors; (2) integrate the JCCC Clinical Program Areas of (A) leukemia (lymphoma, myeloma), BMT, and (B) solid tumor oncology, into the three specific aims noted above; and (3) enhance the SWOG program by using UCLA/JCCC expertise in cancer control, quality of life issues including minority initiatives in breast cancer and lung cancer, survivorship issues for lymphoma patients, and behavioral modification programs. Lastly, the diverse sociocultural atmosphere of Southern California, particularly at OVMC and HGH, provides the University with a large minority patient population. This, along with the designation of UCLA/CHS as a NCI designated Comprehensive Cancer Center, attracts patients seeking new therapeutic modalities and clinical trials and provides a large pool of patients for these studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Internal Medicine/Medicine
Schools of Medicine
Los Angeles
United States
Zip Code
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Smalley, Stephen R; Benedetti, Jacqueline K; Haller, Daniel G et al. (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-33
Berglund, Ryan K; Tangen, Catherine M; Powell, Isaac J et al. (2012) Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology 79:633-7
Marshall, James R; Tangen, Catherine M; Sakr, Wael A et al. (2011) Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4:1761-9
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65
Pisters, Katherine M W; Vallières, Eric; Crowley, John J et al. (2010) Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 28:1843-9

Showing the most recent 10 out of 44 publications